SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Samsara BioCapital, LLC

CIK 0001744967 · 628 MIDDLEFIELD ROAD, PALO ALTO, CA, 94301 · (650) 285-4270

Reported Value
$810M
Q2 2021
Positions
50
Filings on Record
32
2019–present window
Filed
Aug 17, 2021
original filing

Summary

Samsara Biocapital, LLC reported $810M in U.S.-listed holdings across 50 positions for Q2 2021.

The portfolio is heavily concentrated: GRPH alone accounts for 28.2% of reported value.

Compared with Q1 2021, the fund opened 7 new positions and exited 1.

Portfolio Metrics

Turnover
+14.0%
vs prior filed quarter
Top-10 Concentration
+68.2%
share of reported value
Largest Position
+28.2%
Graphite Bio
New / Exited
7 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $104MQ4 ’18Q1 ’19: $127MQ2 ’19: $151MQ3 ’19: $147MQ4 ’19: $209MQ4 ’19Q1 ’20: $174MQ2 ’20: $311MQ3 ’20: $359MQ4 ’20: $994MQ4 ’20Q1 ’21: $542MQ2 ’21: $810MQ3 ’21: $637MQ4 ’21: $515MQ4 ’21Q1 ’22: $397MQ2 ’22: $375MQ3 ’22: $429MQ4 ’22: $465MQ4 ’22Q1 ’23: $486MQ2 ’23: $570MQ3 ’23: $327MQ4 ’23: $643MQ4 ’23Q1 ’24: $646MQ2 ’24: $478MQ3 ’24: $520MQ4 ’24: $729MQ4 ’24Q1 ’25: $561MQ2 ’25: $489MQ3 ’25: $766MQ4 ’25: $969MQ4 ’25Q1 ’26: $1.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 71.4%Other: 23.1%ADR: 5.6%
  • Common Stock · 71.4% · $578M
  • Other · 23.1% · $187M
  • ADR · 5.6% · $45M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GRPHGraphite Bio IncNEW+7.43M7.43M+$228M$228M
260Centessa Pharmaceuticals PLCNEW+1.54M1.54M+$34M$34M
RXRXRecursion Pharmaceuticals IncNEW+775.6K775.6K+$28M$28M
Rain Therapeutics IncNEW+1.64M1.64M+$25M$25M
JANXJanux Therapeutics Inc.NEW+607.9K607.9K+$15M$15M
Elevation Oncology IncNEW+932.2K932.2K+$13M$13M
DAWNGBXDay One BiopharmaceuticalsNEW+202.5K202.5K+$5M$5M
CureVac N.V.SOLD OUT−95.3K0−$9M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1GRPHGraphite Bio Inchistory →COM28.19%$228M7.43M
2NKTXNkarta, Inc.history →COM7.96%$64M2.03M
3Chinook Therapeutics IncCOM5.52%$45M3.17M
4Instil Bio IncCOM5.12%$41M2.15M
5Forma Therapeutics Holdings, Inc.COM4.81%$39M1.57M
6260Centessa Pharmaceuticals PLChistory →SPONS ADS4.22%$34M1.54M
7Sutro BioPharma IncCOM3.85%$31M1.68M
8RXRXRecursion Pharmaceuticals Inchistory →COM3.49%$28M775.6K
9Rain Therapeutics IncCOM3.14%$25M1.64M
10JANXJanux Therapeutics Inc.history →COM1.87%$15M607.9K
11SWTXUSDSpringworks Therapeutics Inchistory →COM1.73%$14M169.9K
12ACRSAclaris Therapeutics, Inc.history →COM1.72%$14M794.2K
13OPHTEURIveric Bio, Inc.history →COM1.66%$13M2.13M
14ICPTUSDIntercept Pharmaceuticals Inchistory →COM1.58%$13M640.7K
15Elevation Oncology IncCOM1.56%$13M932.2K
16ALLKGUSDAllakos Inchistory →COM1.54%$12M146.3K
17BOLT1EURBolt Biotherapeutics, Inchistory →COM1.41%$11M737.5K
18SYRSEURSyros Pharmaceuticals Inchistory →COM1.31%$11M2.19M
19RYIViracta Therapeutics IncCOM1.00%$8M711.0K
20VRNAVerona Pharma PLC.SPONS ADS0.90%$7M1.11M
21Decibel Therapeutics IncCOM0.88%$7M826.4K
22NVV1Novavax, Inc.COM0.79%$6M30.2K
23AGLEUSDAeglea BioTherapeutics, Inc.COM0.76%$6M883.7K
24RYTMRhythm Pharmaceuticals IncCOM0.73%$6M300.3K
25BCTG Acquisition CorpCOM0.70%$6M500.0K
26Jiya Acquisition CorpCOM0.62%$5M507.0K
27DAWNGBXDay One BiopharmaceuticalsCOM0.57%$5M202.5K
28EQEquillium, Inc.COM0.54%$4M738.2K
29EYPTEyepoint Pharmaceuticals IncCOM0.50%$4M450.0K
30Avadel Pharmaceuticals PLCSPONS ADR0.46%$4M549.3K
31430Terns Pharmaceuticals, IncCOM0.44%$4M289.1K
32BDQMAlbireo Pharma, Inc.COM0.43%$4M100.0K
33Atreca IncCOM0.42%$3M396.8K
34Kala Pharmaceuticals IncCOM0.39%$3M601.2K
35BCLS Acquisition CorpCOM0.39%$3M300.0K
36Consonance HFW Acquisition CoCOM0.39%$3M300.0K
37IMCRImmunocore Holdings LimitedSPONS ADS0.31%$2M64.0K
38NVLSEURAlpine Immune Sciences IncCOM0.31%$2M275.2K
39Odonate Therapeutics IncCOM0.30%$2M700.4K
40VTGNUSDVistagen Therapeutics IncCOM0.28%$2M732.6K
41Lifesci Acquisition II CorpCOM0.25%$2M200.0K
42KRON1USDKronos Bio IncCOM0.23%$2M78.1K
43RCKTRocket Pharmaceuticals IncCOM0.22%$2M40.5K
44Allovir, IncCOM0.20%$2M82.3K
45BNTXBioNTech SESPONS ADS0.16%$1M5.8K
46NGM Biopharmaceuticals, Inc.COM0.04%$359,00018.2K
47CATBEURCatabasis Pharmaceuticals IncCOM0.04%$317,000150.0K
48Amarin Corp PLCSPONS ADR NEW0.01%$110,00025.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.0B22May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$969M21Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$766M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$489M29Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$561M37May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$729M43Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$520M42Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$478M40Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$646M39May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$643M41Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$327M41Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$570M47Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$486M56May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022REVEALED$465M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$429M56Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$375M57Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$397M57May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$515M51Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$637M48Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$810M50Aug 17, 202113F-HRchanges · EDGAR ↗
Q1 2021$542M44May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$994M43Feb 17, 202113F-HRchanges · EDGAR ↗
Q3 2020$359M36Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$311M32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$174M28May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$209M19Feb 18, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M18Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$151M21Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$127M18May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$104M17Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.